HMGB4

Across TCGA pan-cancer cohorts, HMGB4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HMGB4 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HMGB4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HMGB4 expression acts as an unfavorable survival marker.

BLCA, STAD, and LUSC are the cancer types where HMGB4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.059	0.720	<.001	24	view →
STAD	OS	Median	III,IV	0.152	0.632	.004	12	view →
LUSC	OS	Median	II,III,IV	0.275	0.734	.025	12	view →
SKCM	DFS	Median	III,IV	0.186	0.659	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HMGB4–BLCA (OS)

Open the BLCA breakdown →